Kaerus Bioscience's KER-0193 Achieves FDA Orphan Drug and Rare Pediatric Designations for Fragile X Syndrome Kaerus Bioscience's lead candidate KER-0193 receives Orphan Drug and Rare Pediatric Drug Designations from the FDA for treating Fragile X syndrome.

Kaerus Bioscience's KER-0193 Achieves FDA Orphan Drug and Rare Pediatric Designations for Fragile X Syndrome #United_States #London #Fragile_X_Syndrome #Kaerus_Bioscience #KER-0193